Former Owner of Chicago Health Care Company Sentenced to a Year in Federal Prison for Billing Medicare for Non-Existent Treatment June 8, 2022
RECOVERY CENTERS OF AMERICA AT ST. CHARLES AND SOUTH ELGIN ANNOUNCE TWO NEW SPECIALIZED TREATMENT PROGRAMS, “DISCOVER” AND “BALANCE” DURING MAY MENTAL HEALTH AWARENESS MONTH May 23, 2022
Wyatt Detention Center to Provide Opioid Use Disorder Treatment to Detainees in Treatment Prior to Detention May 23, 2022
3 Found Guilty of Participating in Scheme to Submit Millions of Dollars in Fraudulent Bills for Substance Abuse Treatment for Teens May 9, 2022
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting May 3, 2022
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting April 25, 2022
Colorado Substance Abuse Treatment Clinic and Owner Agree to Settle False Claims Act Allegations April 18, 2022
Treatment Developed by CHOP Researchers Prevents Hypoglycemia in Children with Hyperinsulinism April 14, 2022
FDA approves CartiHeal’s Implant for the Treatment of Cartilage and Osteochondral Defects March 30, 2022
John Theurer Cancer Center Treats First Patient in U.S. with Investigational New Treatment for Brain Cancer March 29, 2022
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis March 28, 2022
Clearbrook Treatment Centers And Andrew Brown’s Drug Store Agree To Pay The United States Civil Penalties For Violations Of The Controlled Substances Act March 24, 2022
